ProQR Therapeutics (PRQR) Competitors

$1.83 -0.06 (-3.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.90 +0.07 (+3.99%)

As of 09/18/2026 07:57 PM Eastern

PRQR vs. ACRS, DBVT, FDMT, CTMX, and NVCT

Should you buy ProQR Therapeutics stock or one of its competitors? ProQR Therapeutics's main competitors and comparable companies include Aclaris Therapeutics (ACRS), DBV Technologies (DBVT), 4D Molecular Therapeutics (FDMT), CytomX Therapeutics (CTMX), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProQR Therapeutics compare to Aclaris Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

ProQR Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.72	-$47.73M	-$0.46	N/A
Aclaris Therapeutics	$7.83M	98.21	-$64.92M	-$0.58	N/A

ProQR Therapeutics has a net margin of -223.51% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ProQR Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 309.84%. Aclaris Therapeutics has a consensus price target of $11.33, indicating a potential upside of 106.06%. Given ProQR Therapeutics' higher probable upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, Aclaris Therapeutics had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 1 mentions for Aclaris Therapeutics and 0 mentions for ProQR Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat ProQR Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ProQR Therapeutics	Neutral
Aclaris Therapeutics	Positive

ProQR Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Summary

ProQR Therapeutics beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ProQR Therapeutics has a net margin of -223.51% compared to DBV Technologies' net margin of -3,506.53%. ProQR Therapeutics' return on equity of -73.83% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

DBV Technologies has a beta of -0.95, meaning that its stock price is 195% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

In the previous week, DBV Technologies had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 1 mentions for DBV Technologies and 0 mentions for ProQR Therapeutics. DBV Technologies' average media sentiment score of 0.82 beat ProQR Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
ProQR Therapeutics	Neutral

ProQR Therapeutics has higher revenue and earnings than DBV Technologies. ProQR Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	137.69	-$146.95M	-$3.51	N/A
ProQR Therapeutics	$17.99M	10.72	-$47.73M	-$0.46	N/A

DBV Technologies presently has a consensus target price of $48.50, indicating a potential upside of 292.71%. ProQR Therapeutics has a consensus target price of $7.50, indicating a potential upside of 309.84%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ProQR Therapeutics beats DBV Technologies on 11 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

4D Molecular Therapeutics has a net margin of -194.74% compared to ProQR Therapeutics' net margin of -223.51%. 4D Molecular Therapeutics' return on equity of -41.33% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

In the previous week, 4D Molecular Therapeutics had 11 more articles in the media than ProQR Therapeutics. MarketBeat recorded 11 mentions for 4D Molecular Therapeutics and 0 mentions for ProQR Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.52 beat ProQR Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
4D Molecular Therapeutics	Positive
ProQR Therapeutics	Neutral

4D Molecular Therapeutics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

ProQR Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	9.87	-$140.11M	-$2.63	N/A
ProQR Therapeutics	$17.99M	10.72	-$47.73M	-$0.46	N/A

4D Molecular Therapeutics currently has a consensus target price of $28.56, indicating a potential upside of 87.62%. ProQR Therapeutics has a consensus target price of $7.50, indicating a potential upside of 309.84%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

4D Molecular Therapeutics beats ProQR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to CytomX Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

CytomX Therapeutics has higher revenue and earnings than ProQR Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.72	-$47.73M	-$0.46	N/A
CytomX Therapeutics	$76.20M	7.89	-$17.37M	-$0.50	N/A

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ProQR Therapeutics has a net margin of -223.51% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

ProQR Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 309.84%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 331.16%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CytomX Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 0 mentions for ProQR Therapeutics. CytomX Therapeutics' average media sentiment score of 0.22 beat ProQR Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ProQR Therapeutics	Neutral
CytomX Therapeutics	Neutral

ProQR Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Summary

CytomX Therapeutics beats ProQR Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 64.77%. ProQR Therapeutics has a consensus target price of $7.50, indicating a potential upside of 309.84%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nuvectis Pharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. ProQR Therapeutics' return on equity of -73.83% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

In the previous week, Nuvectis Pharma had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for ProQR Therapeutics. Nuvectis Pharma's average media sentiment score of 0.05 beat ProQR Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
ProQR Therapeutics	Neutral

Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Nuvectis Pharma has higher earnings, but lower revenue than ProQR Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
ProQR Therapeutics	$17.99M	10.72	-$47.73M	-$0.46	N/A

Summary

Nuvectis Pharma and ProQR Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$199.13M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-3.98	14.08	273.81	25.39
Price / Sales	10.72	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	3.45	15.45	10.45	6.33
Net Income	-$47.73M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-1.61%	-1.22%	0.88%	1.17%
1 Month Performance	-17.57%	-4.44%	-1.59%	-2.59%
1 Year Performance	-12.86%	37.78%	18.08%	5.97%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	3.4232 of 5 stars	$1.83 -3.2%	$7.50 +309.8%	-16.4%	$199.13M	$17.99M	N/A	166
ACRS Aclaris Therapeutics	2.1824 of 5 stars	$6.06 -1.8%	$11.33 +87.0%	+182.1%	$862.72M	$7.83M	N/A	100	High Trading Volume
DBVT DBV Technologies	3.4495 of 5 stars	$13.27 -1.5%	$48.50 +265.5%	+28.8%	$846.93M	$5.64M	N/A	80
FDMT 4D Molecular Therapeutics	3.1258 of 5 stars	$14.63 -2.3%	$29.63 +102.5%	+114.4%	$827.01M	$85.21M	N/A	120	News Coverage Insider Trade Gap Up
CTMX CytomX Therapeutics	2.3603 of 5 stars	$3.65 -1.6%	$11.90 +226.0%	+35.3%	$808.41M	$76.20M	N/A	170	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. ACRS, DBVT, FDMT, CTMX, and NVCT

How does ProQR Therapeutics compare to Aclaris Therapeutics?

Summary

How does ProQR Therapeutics compare to DBV Technologies?

Summary

How does ProQR Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does ProQR Therapeutics compare to CytomX Therapeutics?

Summary

How does ProQR Therapeutics compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. ACRS, DBVT, FDMT, CTMX, and NVCT

How does ProQR Therapeutics compare to Aclaris Therapeutics?

Which has higher valuation and earnings, PRQR or ACRS?

Is PRQR or ACRS more profitable?

Do insiders & institutionals have more ownership in PRQR or ACRS?

Do analysts recommend PRQR or ACRS?

Does the media favor PRQR or ACRS?

Which has more volatility and risk, PRQR or ACRS?

Summary

How does ProQR Therapeutics compare to DBV Technologies?

Do institutionals & insiders believe in DBVT or PRQR?

Is DBVT or PRQR more profitable?

Which has more risk and volatility, DBVT or PRQR?

Does the media prefer DBVT or PRQR?

Which has preferable earnings & valuation, DBVT or PRQR?

Do analysts recommend DBVT or PRQR?

Summary

How does ProQR Therapeutics compare to 4D Molecular Therapeutics?

Do institutionals & insiders believe in FDMT or PRQR?

Is FDMT or PRQR more profitable?

Does the media prefer FDMT or PRQR?

Which has more volatility and risk, FDMT or PRQR?

Which has stronger earnings & valuation, FDMT or PRQR?

Do analysts rate FDMT or PRQR?

Summary

How does ProQR Therapeutics compare to CytomX Therapeutics?

Which has preferable valuation & earnings, PRQR or CTMX?

Do institutionals & insiders hold more shares of PRQR or CTMX?

Is PRQR or CTMX more profitable?

Do analysts rate PRQR or CTMX?

Does the media prefer PRQR or CTMX?

Which has more risk and volatility, PRQR or CTMX?

Summary

How does ProQR Therapeutics compare to Nuvectis Pharma?

Do analysts recommend NVCT or PRQR?

Do insiders & institutionals have more ownership in NVCT or PRQR?

Is NVCT or PRQR more profitable?

Does the media refer more to NVCT or PRQR?

Which has more risk & volatility, NVCT or PRQR?

Which has preferable valuation & earnings, NVCT or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools